Table 4.

Clinical Utility Parameters for Incident CHD for the Two GRS among GERA Subjects of Minority Descent Classified as Intermediate Risk.

	Individuals to be treated (A)	Events predicted at 10 years (B)	Events potentially prevented (C = B*0.24)	Individuals needed to treat to prevent 1 CHD event (D = A/C)	Efficiency of the two-stage vs. one-stage approach
	African-Americans (n = 2,089)
One-stage Screening	473	41	9.8	47	1
Two-stage Screening
GRS_12	33	4	1.0	33	1.4 (47/33)
GRS_51	12	3	0.7	17	2.8 (47/17)
	Latinos (n = 4,349)
One-stage Screening	876	48	11.5	73	1
Two-stage Screening
GRS_12	31	6	1.4	22	3.3 (73/22)
GRS_51	39	9	2.2	19	3.8 (73/19)
	Asians (n = 4,804)
One-stage Screening	830	46	11.0	75	1
Two-stage Screening
GRS_12	19	2	0.5	38	2.0 (75/38)
GRS_51	24	2	0.5	48	1.6 (75/48)
	All Minority Groups Combined (n = 11,242)
One-stage Screening	2179	135	32.4	68	1
Two-stage Screening
GRS_12	59	11	2.6	23	2.9 (68/23)
GRS_51	30	7	1.7	18	3.8 (68/18)

CHD denotes coronary heart disease; GRS denotes genetic risk score.